Merck and Samsung Bioepis Launch Biosimilar Early, After SCOTUS Ruling

By Sam | August 4, 2017

Samsung Bioepis and Merck announced the U.S. launch of Renflexis (infliximab-abda), a biosimilar of Janssen’s Remicade (infliximab).
Source: Generic Line

Posted in Generic Line